Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Earnings Movers | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Down | Weakness | 0.00% | |
New Uptrend | Bullish | -10.12% | |
Calm After Storm | Range Contraction | -10.12% | |
Upper Bollinger Band Walk | Strength | -10.12% | |
Earnings Movers | Other | -10.12% | |
Wide Bands | Range Expansion | -10.12% |
Alert | Time |
---|---|
10 DMA Resistance | about 23 hours ago |
5x Volume Pace | about 23 hours ago |
2x Volume Pace | about 24 hours ago |
1.5x Volume Pace | about 24 hours ago |
3x Volume Pace | about 24 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 10/31/2024
Syros Pharmaceuticals, Inc. Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Medication Acute Myeloid Leukemia Leukemia Myelodysplastic Syndrome Immune Mediated Diseases Acute Leukemia Refractory Acute Myeloid Leukemia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.17 |
52 Week Low | 1.43 |
Average Volume | 345,677 |
200-Day Moving Average | 4.74 |
50-Day Moving Average | 1.92 |
20-Day Moving Average | 2.13 |
10-Day Moving Average | 2.30 |
Average True Range | 0.25 |
RSI (14) | 53.05 |
ADX | 25.19 |
+DI | 31.04 |
-DI | 20.69 |
Chandelier Exit (Long, 3 ATRs) | 2.02 |
Chandelier Exit (Short, 3 ATRs) | 2.57 |
Upper Bollinger Bands | 2.56 |
Lower Bollinger Band | 1.69 |
Percent B (%b) | 0.66 |
BandWidth | 40.93 |
MACD Line | 0.09 |
MACD Signal Line | 0.04 |
MACD Histogram | 0.0457 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.66 | ||||
Resistance 3 (R3) | 2.64 | 2.48 | 2.60 | ||
Resistance 2 (R2) | 2.48 | 2.38 | 2.49 | 2.57 | |
Resistance 1 (R1) | 2.37 | 2.32 | 2.43 | 2.40 | 2.55 |
Pivot Point | 2.22 | 2.22 | 2.24 | 2.23 | 2.22 |
Support 1 (S1) | 2.11 | 2.12 | 2.16 | 2.13 | 1.98 |
Support 2 (S2) | 1.95 | 2.05 | 1.96 | 1.96 | |
Support 3 (S3) | 1.84 | 1.95 | 1.93 | ||
Support 4 (S4) | 1.87 |